Dublin, Dec. 06, 2018 (GLOBE NEWSWIRE) -- The "House Dust Mite Allergy - Market Insights, Epidemiology and Market Forecast" drug pipelines has been added to ResearchAndMarkets.com's offering.

This report delivers an in-depth understanding of the disease, historical & forecasted epidemiology trends in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of House Dust Mite Allergy from 2016 to 2027 segmented by the US, EU-5 countries and Japan.

The report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Disease Understanding and Treatment Algorithm

The House Dust Mite Allergy market report gives the thorough understanding of the House Dust Mite Allergy by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends, treatment algorithms and treatment guidelines in the US, Europe, and Japan.

Epidemiology

The disease epidemiology covered in the report is segmented into two parts: Total Prevalent Population of Respiratory Allergy and Total Prevalence of House Dust Mite (HDM) Induced Respiratory Allergies in 7 Major Markets [United States and EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan].

According to the publisher, the prevalent cases of House Dust Mite Induced Respiratory Allergy was 50,703,100 in 2016 in 7MM and, is expected to increase during the study period i.e., 2016-2027. Among 7MM, United States account for highest prevalent cases of House Dust Mite Allergy with 69,310,852 prevalent cases in 2016.

Drug Chapters

House Mite Allergy is a hypersensitive (IgE mediated) reaction to proteins in the excrement of dust mites. These proteins can cause an allergic reaction in the respiratory passages causing the symptoms of hay fever and asthma. It can often aggravate atopic dermatitis (eczema) in people who have this problem, causing facial eczema that can be difficult to treat. Odactra by Merck Sharp & Dohme Corp. and Actair by Shionogi & Co. are currently approved therapies for House Dust Mite Allergies.

Market Outlook

The report provides global market share of House Dust Mite Allergy i.e., 7 Major Markets [United States and EU5 (Germany, Spain, Italy, France and United Kingdom)] and Japan. In 2016, global market size of House Dust Mite Allergy was USD 258 million and, is expected to grow during the forecast period of 2018-2027.

The region-wise market size for House Dust Mite Allergy in US, EU-5 countries (Germany, France, Italy, Spain and the U.K.) and Japan shows highest market size in US, followed by Germany, the lowest being in the Spain.

Companies Featured

• Merck Sharp & Dohme Corp.
• Shionogi & Co.

Key Topics Covered

1. Key Insights

2. House Dust Mite Allergy Market Overview at a Glance
2.1. Market Share (%) Distribution of House Dust Mite Allergy in 2017
2.2. Market Share (%) Distribution of House Dust Mite Allergy in 2027

3. House Dust Mite Allergy: Disease Background and Overview
3.1. Introduction
3.2. Classification of House Dust Mites (HDM)
3.3. HDM Anatomy and Feeding
3.4. Clinical Signs and Symptoms
3.5. Factors Influencing Exposure, Sensitization, and Allergy to HDM
3.6. Atopic Sensitization to Dust Mites
3.7. HDMs in allergic disease
3.8. Diagnosis
3.9. Management
3.10. Current Therapeutic Strategies

4. Epidemiology and Patient Population
4.1. Key Findings

5. 7MM Total Prevalence of HDM Induced Respiratory Allergy

6. Country Wise-Epidemiology of House Dust Mite Allergy
6.1. United States
6.2. EU5 Countries
6.3. Germany
6.4. France
6.5. Italy
6.6. Spain
6.7. United Kingdom
6.8. Japan
6.9. Treatment Algorithm

7. Unmet Needs

8. Marketed Drug Analysis
8.1. Odactra: Merck Sharp & Dohme Corp.
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Safety and Efficacy
8.1.6. Product Profile
8.2. Actair: Shionogi & Co.
8.2.1. Drug Description
8.2.2. Regulatory Milestones
8.2.3. Mechanism of Action
8.2.4. Advantages & Disadvantages
8.2.5. Safety and Efficacy
8.2.6. Product Profile

9. House Dust Mite Allergy: 7 Major Market Analysis
9.1. Key Findings
9.2. Market Size of House Dust Mite Allergy in 7MM
9.3. Market size of House Dust Mite Allergy by Therapy-Type in 7MM
9.4. Market Size of House Dust Mite Allergy by therapies in 7MM

10. The United States Market Outlook
10.1. United States Market Size
10.2. Total Market size of House Dust Mite Allergy in the United States
10.3. Market size of House Dust Mite Allergy by Therapy-type in the United States
10.4. Market Size of House Dust Mite Allergy by Therapies in the US

11. EU-5 Countries: Market Outlook
11.1. Germany
11.2. France
11.3. Italy
11.4. Spain
11.5. United Kingdom
11.6. Japan: Market Outlook

12. Market Drivers

13. Market Barriers

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/4h293q/house_dust_mite?w=12

CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Press Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
Related Topics: Allergy Drugs 

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.